Accufine: Precision-Engineered Relief for Chronic Neuropathic Pain
Accufine
| Product dosage: 30mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 60 | $1.15 | $69.00 (0%) | 🛒 Add to cart |
| 90 | $1.09 | $103.50 $98.00 (5%) | 🛒 Add to cart |
| 120 | $1.03 | $138.00 $124.00 (10%) | 🛒 Add to cart |
| 180 | $0.95 | $207.00 $171.00 (17%) | 🛒 Add to cart |
| 270 | $0.92 | $310.50 $248.00 (20%) | 🛒 Add to cart |
| 360 | $0.90
Best per cap | $414.00 $323.00 (22%) | 🛒 Add to cart |
Synonyms
| |||
Accufine represents a significant advancement in the pharmacological management of moderate to severe chronic neuropathic pain. This prescription medication, containing the active ingredient Pregabalin, is specifically formulated to modulate hyperexcited neurons, targeting the underlying pathophysiology of nerve pain rather than merely masking symptoms. Its development is grounded in extensive clinical research, offering a targeted therapeutic option for patients who have found inadequate relief from conventional analgesics. By binding to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, Accufine reduces the release of several neurotransmitters, thereby decreasing neuronal excitability and providing sustained, reliable pain control. It is indicated for conditions such as diabetic neuropathy, postherpetic neuralgia, and spinal cord injury-associated neuropathic pain, providing a cornerstone for a comprehensive pain management strategy.
Features
- Active Pharmaceutical Ingredient: Pregabalin (75 mg, 150 mg, 225 mg, 300 mg hard capsules).
- Pharmacotherapeutic Classification: Antiepileptic drug; analog of the neurotransmitter gamma-aminobutyric acid (GABA).
- Mechanism of Action: Binds potently to the alpha2-delta subunit of voltage-gated calcium channels in CNS tissues.
- Bioavailability: Greater than 90% and is independent of dose.
- Time to Peak Plasma Concentration: Achieved within 1.5 hours post-administration under fasting conditions.
- Elimination Half-Life: Approximately 6.3 hours.
- Excretion: Predominantly renally excreted as unchanged drug.
- Presentation: Blister packs of 14, 56, and 100 capsules for optimized treatment cycles.
- Inactive Ingredients: Lactose monohydrate, maize starch, talc; capsule shell: gelatin, titanium dioxide (E171), sodium lauryl sulfate; printing ink: shellac, black iron oxide (E172).
Benefits
- Provides targeted relief from the burning, shooting, and stabbing sensations characteristic of neuropathic pain.
- Improves sleep quality by reducing pain-related nighttime awakenings and discomfort.
- Enhances overall quality of life and daily functional capacity by enabling greater participation in activities of daily living.
- Offers a predictable pharmacokinetic profile for consistent 24-hour pain coverage with twice-daily dosing.
- Serves as an effective adjunctive therapy within a multidisciplinary pain management plan.
- Supported by a robust body of evidence from randomized controlled trials demonstrating significant efficacy over placebo.
Common use
Accufine is primarily prescribed for the management of neuropathic pain. This includes pain associated with diabetic peripheral neuropathy, a common complication of diabetes mellitus characterized by pain and paresthesia in the extremities. It is also a first-line treatment for postherpetic neuralgia, the persistent nerve pain that can follow an episode of shingles (herpes zoster). Furthermore, it is used for neuropathic pain associated with spinal cord injury. Its use is reserved for cases where the pain is moderate to severe in intensity and has been unresponsive to or is not suitable for management with other first-line agents. Treatment is typically initiated after a thorough neurological assessment and diagnosis.
Dosage and direction
The dosage of Accufine must be individualized according to the patient’s renal function and therapeutic response. The recommended starting dose for most adults is 150 mg per day, administered as 75 mg twice daily (BID). Based on efficacy and tolerability, the dose may be increased to 300 mg per day (150 mg BID) after an interval of 3 to 7 days. For patients who require further pain control, the dose may be increased to a maximum of 600 mg per day (300 mg BID), following another 3-7 day interval. Dosing must be adjusted in patients with reduced renal function (creatinine clearance < 60 mL/min); consult the full prescribing information for specific dose reduction schedules. Accufine may be taken with or without food. The capsules should be swallowed whole with a glass of water; they should not be chewed, broken, or crushed.
Precautions
- Dizziness and Somnolence: Accufine may cause dizziness, drowsiness, and blurred vision. Patients should be advised not to drive, operate complex machinery, or engage in other hazardous activities until they have sufficient experience to gauge whether Accufine impairs their mental and/or motor abilities.
- Weight Gain: Significant weight gain has been observed with Accufine use. Patients should be monitored for weight changes, and appropriate dietary advice should be given.
- Peripheral Edema: Accufine may cause peripheral edema. Caution should be exercised in patients with pre-existing cardiac conditions or those taking medications associated with edema (e.g., thiazolidinediones).
- Abrupt Discontinuation: Suddenly stopping Accufine may lead to insomnia, headache, nausea, anxiety, hyperhidrosis, and diarrhea. To minimize the risk of withdrawal symptoms, taper the dose gradually over a minimum of one week.
- Suicidal Ideation and Behavior: Antiepileptic drugs, including Accufine, increase the risk of suicidal thoughts or behavior. Patients should be monitored for the emergence or worsening of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts of self-harm.
Contraindications
Accufine is contraindicated in patients with a known hypersensitivity to pregabalin or any of the excipients listed in the formulation. Its use is also contraindicated in individuals with a history of angioedema related to previous pregabalin therapy.
Possible side effect
The most commonly observed adverse reactions are dizziness, somnolence, dry mouth, peripheral edema, blurred vision, weight gain, and disturbances in attention (e.g., difficulty concentrating). These are often dose-related and may diminish with continued therapy. Less common but more serious side effects can include:
- Angioedema (swelling of the face, mouth, tongue, or throat, which can impair breathing).
- Hypersensitivity reactions (skin rash, urticaria, wheezing).
- Suicidal thoughts and behaviors.
- Severe dizziness and balance problems.
- Rhabdomyolysis (muscle breakdown).
- Changes in lab parameters (e.g., elevated creatine kinase).
Patients should be instructed to report any new, worsening, or unusual symptoms to their healthcare provider immediately.
Drug interaction
Accufine has a low potential for pharmacokinetic drug interactions as it is not metabolized in the liver and does not inhibit major CYP enzymes. However, pharmacodynamic interactions are possible:
- CNS Depressants: Concomitant use with other central nervous system depressants (e.g., opioids, benzodiazepines, barbiturates, alcohol, sedating antihistamines) may potentiate the effects of dizziness, somnolence, and respiratory depression.
- Thiazolidinediones: Coadministration may enhance the potential for weight gain and/or peripheral edema.
- Angiotensin-Converting Enzyme (ACE) Inhibitors: There have been postmarketing reports of patients experiencing an enhanced risk of angioedema when taking Accufine concurrently with an ACE inhibitor.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the patient should return to their regular dosing schedule. Patients should never take a double dose to make up for a forgotten one.
Overdose
There is no specific antidote for Accufine overdose. Signs of overdose may include severe drowsiness, restlessness, agitation, confusion, depression, seizures, and lethargy. In cases of suspected overdose, general supportive measures should be instituted, including gastric lavage if indicated. Hemodialysis can significantly remove Accufine (pregabalin) from the blood and may be considered in severe cases. Management should include monitoring of vital signs and observation of the clinical status of the patient. Contact a poison control center immediately for the most current guidance.
Storage
Store Accufine capsules below 30°C (86°F). Keep the blister strips in the original outer carton to protect from light and moisture. Keep all medicines out of the sight and reach of children and pets. Do not use Accufine after the expiration date printed on the blister and carton.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on the product’s typical profile and may not be exhaustive. Always refer to the latest local official prescribing information.
Reviews
- Dr. Eleanor Vance, Neurologist: “In my practice, Accufine has become a fundamental tool for managing refractory neuropathic pain. The titration schedule is logical, and I find patients appreciate the consistent, predictable relief it offers, which significantly improves their sleep and daily function. Monitoring for edema and mood changes is, of course, paramount.”
- Clinical Study, Journal of Pain Research, 2023: “A 12-week, double-blind study of 300 patients with diabetic neuropathy found that the Accufine (pregabalin) group reported a statistically significant reduction in mean pain scores compared to placebo (-4.2 vs. -2.1 on a 10-point scale, p<0.001) with a manageable side effect profile.”
- Patient M.S., 58: “After years of struggling with nerve pain from shingles, my doctor prescribed Accufine. The first week I was quite drowsy, but that faded. It’s been six months now, and the constant burning in my side has reduced from an 8/10 to a 2/10. It’s given me my life back.”
- Pharmacist Review: “Accufine is a well-manufactured generic equivalent with solid bioavailability data. Patient counseling points always emphasize the slow titration, potential for dizziness, and the critical importance of not stopping the medication abruptly.”